A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting

Trial Profile

A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs PINTA 745 (Primary)
  • Indications Nutrition disorders
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Pinta Biotherapeutics
  • Most Recent Events

    • 31 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 14 Dec 2015 Results published in an Atara Biotherapeutics media release.
    • 14 Dec 2015 Primary endpoint of 'Percent Changes in Lean Body Mass (LBM)' has not been met, according to an Atara Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top